Ferroptosis is an iron-dependent cell death pathway that is different from apoptosis, pyroptosis, and necrosis. The main characteristics of ferroptosis are the Fenton reaction mediated by intracellular free divalent iron ions, lipid peroxidation of cell membrane lipids, and inhibition of the anti-lipid peroxidation activity of intracellular glutathione peroxidase 4 (GPX4). Recent studies have shown that ferroptosis can be involved in the pathological processes of many disorders, such as ischemia– reperfusion injury, nervous system diseases, and blood diseases. However, the specific mechanisms by which ferroptosis participates in the occurrence and development of acute leukemia still need to be more fully and deeply studied. This article reviews the characteristics of ferroptosis and the regulatory mechanisms promoting or inhibiting ferroptosis. More importantly, it further discusses the role of ferroptosis in acute leukemia and predicts a change in treatment strategy brought about by increased knowledge of the role of ferroptosis in acute leukemia.
Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
The concept of ferroptosis, which is defined as iron-dependent regulated cell death, was put forward in 2012, and the main causes of ferroptosis are lipid peroxidation and plasma membrane rupture.[1,2,3] Ferroptosis is different from the common forms of regulated cell death previously discovered, such as apoptosis, pyroptosis, and necroptosis.[4] Apoptosis is mediated by molecules such as caspases 3/6/7/8/9, poly (adenosine diphosphate [ADP]-ribose) polymerases (PARP), B-cell lymphoma-2 (BCL2), BCL2 associated X (BAX), and BCL2 antagonist/killer 1 (BAK1). Pyroptosis also depends on the role of caspases, of which caspases 1/4/5/11 play a major role. In addition, pyroptosis is also regulated by gasdermin D (GSDMD), interleukin-1 beta (IL-1B), and interleukin-18 (IL-18). Necroptosis does not depend on the function of caspases; instead, receptor-interacting protein kinase 1 (RIPK1), RIPK, and mixed lineage kinase domain-like protein (MLKL) mediate its effects.[2,5] Studies have found that dozens of key cytokines, mainly including nuclear receptor coactivator 4 (NCOA4), arachidonate 15-lipoxygenase (ALOX15), voltage-dependent anion-selective channel protein 2 (VDAC2/3), solute carrier family 7 member 11 (SLC7A11), solute carrier family 3 member 2 (SLC3A2), glutathione peroxidase 4 (GPX4), transferrin receptor (TFR), transferrin (TF), and ferritin, are involved in the regulation of ferroptosis.
The main characteristics of ferroptosis are iron accumulation and excessive lipid peroxidation.[1,6,7] In recent years, there have been an increasing number of in-depth studies on the mechanism of ferroptosis. The system Xc− cystine/glutamate antiporter and GPX4 have been found to be involved in ferroptosis, and using the compounds erastin and an inhibitor of GPX4 (RSL3), respectively, to inhibit these two molecules can induce ferroptosis.[1,8,9,10] Uncontrolled lipid peroxidation is a sign of ferroptosis. Some studies have found that acyl-coenzyme A (acyl-CoA) synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3) are important factors driving ferroptosis.[11,12,13] Furthermore, certain lipoxygenases (LOX) can directly oxidize polyunsaturated fatty acids (PUFAs) on biofilms and thus are also considered to have a great potential to mediate ferroptosis.[14] An increasing number of studies have revealed the regulatory mechanism of ferroptosis, providing a sufficient theoretical basis for ferroptosis to be used to enhance treatment strategies in the future.
Leukemia is a group of heterogeneous hematopoietic stem cell (HSC) malignant tumors. Leukemic cells are abnormally aggregated and undifferentiated primordial cells, which can proliferate unrestrictedly in the bone marrow and interfere with the production of normal blood cells. Leukemia can be divided into acute and chronic leukemia. Acute leukemia (AL) contains acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). For now, there are many ways to treat leukemia clinically, but because of drug resistance or relapse, leukemia patients still need more treatment strategies.[15,16,17,18] A number of experiments and epidemiological studies have shown that iron metabolism disorders are related to the occurrence and development of AL.[19,20,21] The occurrence of leukemia involves many genes related to iron metabolism, including hemochromatosis (HFE) gene, transferrin receptor 1 gene, and other genes involved in iron metabolism. Leukemic cells showed an increase in iron uptake and a decrease in iron efflux, resulting in an increase in cellular iron levels.[7,22]
At present, the main methods for the clinical treatment of leukemia are chemotherapy and bone marrow transplantation.[23,24] However, traditional chemotherapy drugs not only kill leukemia cells but also cause damage to healthy cells, causing huge side effects, and bone marrow transplantation is not suitable for all leukemia patients for various reasons. Although the development of chimeric antigen receptor (CAR)-T therapy provides a new hope for the treatment of leukemia, it is still not widely used because of its high price, troublesome preparation, and other limitations.[25] Leukemic cells are more easily affected by iron depletion than normal cells. Therefore, targeting the iron metabolic pathway may provide a good strategy for the treatment of AL. Ferroptosis is a newly discovered way of cell death. The rational use of ferroptosis will provide a new dawn for the treatment of AL.[26]
As early as 1980, it was found that system Xc− could transport cystine into cells in exchange for glutamate.[27] It has been reported that inhibition of cystine transport can induce glutamate toxicity in nerve cells and produce oxidative stress.[28] In 1997, studies showed that inhibition of arachidonate 12-lipoxygenase (Alox12) could inhibit glutamate-induced cell death in the hippocampal cell line HT22 and primary cortical neurons.[29] In 2003, erastin, an inducer of ferroptosis, was discovered in high-throughput small-molecule screening studies. Erastin have lethal effects on rat sarcoma (RAS)-mutant tumor cells.[30] In 2012, the concept of ferroptosis was formally proposed, and studies have found that erastin induces cell death by inhibiting cystine uptake via system Xc−.[1] Soon after in 2014, another important molecule related to ferroptosis, GPX4, was discovered. Yang et al[8] reported that GPX4 can prevent ferroptosis by reducing phospholipid hydrogen peroxide, thereby inhibiting LOX-mediated lipid peroxidation. Two years later, it was reported that PUFA oxidation by LOX triggers ferroptosis.[31] In 2017, studies showed that ACSL4 is a biomarker of and plays a key role in ferroptosis and is necessary to produce the PUFAs needed for ferroptosis.[12] In 2018, a study of GPX4 showed that selenium was necessary for GPX4 to inhibit ferroptosis.[32] Recently, studies have shown that the coenzyme Q10 (CoQ10) reductase ferroptosis suppressor protein 1 (FSP1) can inhibit ferroptosis in a glutathione (GSH)-independent manner, providing a new pathway for the study of ferroptosis.[33,34] In a 2020 study to identify ferroptosis-sensitive genes, we found that oxidizing organelle peroxisomes can increase ferroptosis sensitivity through the synthesis of polyunsaturated fatty ether phospholipids.[35] With more in-depth research, it has been found that there is a strong relationship between ferroptosis and the immune system. Follicular helper T (Tfh) cells are a specialized subset of cluster of differentiation 4 (CD4) T cells that essentially support germinal center responses generating high-affinity and long-lived humoral immunity. The regulation of T cell survival remains unclear. Kuhn’s findings reveal the central role of the selenium – GPX4 – ferroptosis axis in regulating Tfh homeostasis, which can be targeted to enhance T cells’ function in infection and following vaccination [Figure 1].
Ferroptosis is different from other forms of regulated cell death, such as apoptosis, pyroptosis, and necroptosis, in terms of morphological characteristics, biochemical immune characteristics, and genetic regulation. Ferroptosis is characterized by the following morphological features: (1) a significantly decreased mitochondrial crest, increased membrane density, and rupture of the membrane, leading to atrophy of mitochondria; (2) a normal nucleus; and (3) increased cell membrane density and a disintegrated cell membrane. Ferroptosis is characterized by the following biochemical and immune characteristics: (1) apparently decreased mitochondrial membrane potential; (2) significantly increased intracellular iron ion level; (3) markedly increased reactive oxygen species (ROS) level; (4) enhanced lipid peroxidation; (5) release of injury-related molecular factors that promote the inflammatory response; and (6) caspase independence.[1,5,36,37,38]
The main features of ferroptosis are increased iron and the accumulation of lipid peroxides on the membrane.[2] The core function of ferroptosis is to balance oxidative damage and antioxidant defense[3,39] [Figure 2].
Lipid peroxidation refers to the loss of hydrogen atoms by lipids under the action of free radicals or lipid peroxidases, which leads to the oxidation, breaking, and shortening of lipid carbon chains and the production of cytotoxic substances such as lipid free radicals, lipid hydroperoxides, and active aldehydes, resulting in cell damage.[40] PUFAs, an important component of the cell membrane, are the main substrate of lipid peroxidation during ferroptosis. PUFAs are long-chain fatty acids with more than two double bonds that regulate many important physiological activities, such as growth, proliferation, differentiation, senescence, immunity, and inflammation. PUFAs are easily oxidized, and the more double bonds they contain, the higher their oxidation sensitivity.[41,42,43,44,45,46] Some studies have shown that ROS mainly attacks PUFAs located on the cell membrane. Lipid peroxidation of PUFAs begins with the formation of lipid free radicals. Subsequently, lipid free radicals interact with oxygen molecules to form lipid peroxidation free radicals. Lipid peroxidation free radicals can continuously participate in the oxidation of PUFAs; as such, the lipid peroxidation of PUFAs occurs via a cascade reaction. The PUFAs that participate in the induction of ferroptosis are mainly arachidonic acid (AA) and adrenic acid (AdA).[47] Furthermore, ACSL4 and lysophosphatidylcholine acyltransferase 3 (LPCAT3) also play an important role in this process. It has been reported that reducing ACSL4 can reduce the sensitivity of cells to iron-related death, while upregulation of ACSL4 expression after inhibition of the nuclear factor E2-related factor 2 (NRF2)-yes1 associated transcriptional regulator (YAP) pathway can promote ferroptosis.[48,49,50] LPCAT3 targets acetylated AA and esterifies CoA-AA intermediates to form arachidonic acid-phosphatidylethanolamine PE-AA, which ultimately leads to ferroptosis under the action of LOX.[13,46,51] In recent years, because LOX can oxidize PUFAs located on the cell membrane, researchers have begun to explore whether LOX can mediate ferroptosis.[14] It has been reported that ferroptosis induced by 12-LOX can promote the inhibition of p53-dependent tumors.[52] The application of LOX inhibitors can inhibit ferroptosis.[29,53] However, since more experimental evidence is needed to determine whether LOX is directly related to ferroptosis, we cannot conclude that LOX can mediate ferroptosis.
Iron is a necessary nutrient for living creatures. The level of iron in cells is a result of the balance between the absorption, output, utilization, and storage of iron. When ferroptosis occurs, a large amount of free divalent Fe2+ accumulates in cells, which mainly comes from the binding of TF with Fe3+ to TFR on the plasma membrane. TF enters the cell, and Fe3+ dissociates from TF and is reduced to Fe2+ or combines with ferritin to be stored in the iron pool. Additionally, ferritin in the iron pool can be degraded, which releases a large amount of divalent iron ions, in a process mediated by nuclear receptor coactivator 4 (NCOA4), serving as another source of free Fe2+.[54,55,56] Current studies suggest that excess iron can promote lipid peroxidation and then induce ferroptosis by two main mechanisms, namely, the generation of ROS via the iron-dependent Fenton reaction and the activation of iron-containing enzymes (e.g., LOX).[2,57] In the Fenton reaction, extremely oxidative free Fe2+ easily reacts with H2O2 to produce hydroxyl radicals that can cause oxidative damage to deoxyribonucleic acid (DNA), proteins, and membrane lipids, promoting lipid peroxidation, damaging the cell membrane, and eventually leading to cell death. Fenton’s reaction formula is Fe2+ + H2O2 → Fe3+ + (OH)－ + OH·.[38] In addition, studies have shown that the enzymes LOX and nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome P450 reductase (POR), which are related to phospholipid peroxidation, require iron catalysis to participate in ferroptosis.[10,58]
GPX4 is a selenium-containing cysteine and GSH-dependent enzyme belonging to the GSH peroxidase family (including GPX1-8). It is a necessary enzyme that scavenges lipid hydrogen peroxide by reducing it to the corresponding ethanol or reducing H2O2 to free H2O2 and water. As such, GPX4 plays an important role in preventing ferroptosis.[59,60,61] In recent years, studies have shown that the cystine-importing GSH-GPX4 machinery plays an important role in the prevention of ferroptosis, and it has been proven that phospholipid hydroperoxide (PLOOH) is a substrate of GPX4 and might be an executor of ferroptosis.[62] GSH is synthesized by the catalysis of the cytosolic enzymes glutamate cysteine ligase (GCL) and glutathione synthetase (GSS) and participates in the regulation of ferroptosis.[63] GSH can produce glutathione disulfide (GSSG), and GSSG regenerates GSH through glutathione reductase (GR). In this process, GSH can act as an electron donor, so GSH is necessary for the GPX4 catalytic reaction and an important factor for maintaining the activity of GPX4. Because GSH participates in maintaining the activity of GPX4, GPX4 can prevent ferroptosis. In addition, cystine is the most restricted amino acid in the process of GSH synthesis, so the cystine-importing GSH-GPX4 machinery is the most critical signaling pathway for preventing ferroptosis. It has been reported that the cystine/glutamate antiporter system Xc− can promote ferroptosis by inhibiting cysteine import.[1,64,65] Additionally, erastin can inhibit cysteine input and inactivate GPX4 indirectly, resulting in the accumulation of PLOOH, a substrate of GPX4, and the accumulation of PLOOH can quickly initiate the Fenton reaction; in addition, the amount of PLOOH can be rapidly increased, resulting in ferroptotic cell death. Selenium is an essential element for organisms and participates in many important physiological processes in the body.[34] In addition to the cystine-importing GSH-GPX4 signaling pathway, selenium can also affect the expression of GPX4 and induce ferroptosis. It has been suggested that selenium can regulate GPX4 expression by increasing ribosome transfer RNA (tRNA) density downstream of UGA-Sec codons and selenium incorporation efficiency in part by affecting the degree of Sec-tRNA[Ser]SecUm34 methylation. Sec-tRNA must first be activated by the addition of an isopentenyl lipid group, a product of the mevalonate (MVA) pathway. This phenomenon may explain how disruption of the MVA pathway by statins leads to reduced GPX4 expression and increased ferroptosis in certain cells.[66,67,68,69]
To date, the most important signaling axis known to regulate ferroptosis is dependent on GPX4. Inhibition of GPX4 to induce ferroptosis is a new therapeutic strategy for the treatment of tumors. However, different cell lines have different sensitivities to GPX4 inhibitors. Therefore, we speculate that there are other mechanisms regulating ferroptosis in the body that do not depend on GPX4.[11] Through CRISPR/cas9 screening, Doll et al[33] found that FSP1 is an anti-ferroptosis gene.[34] Other studies on FSP1 have proven that FSP1 is a powerful ferroptosis inhibitor independent of GPX4, GSH, or ACSL4.[34] FSP1 was initially reported to be involved in p53-mediated apoptosis because its amino acid sequence is similar to that of human apoptosis-inducing factor (AIF), so it is also called AIF-like mitochondrion-associated inducer of death (AMID).[70,71,72] Many studies have shown that FSP1 can regulate the ferroptosis sensitivity of cells. FSP1 is an oxidoreductase that can reduce CoQ10 to ubiquinol, which is a lipophilic free radical-trapping antioxidant that can prevent lipid peroxidation. Therefore, FSP1 inhibits ferroptosis through this process.[34]
The study of Chen et al[73] shows that the inhibition of ferroptosis by FSP1 is independent of GPX4, and the myristoylation of FSP1 mediates the recruitment of FSP1 to the cell membrane, which plays an important role in the inhibition of ferroptosis by FSP1. In addition to FSP1 and GPX4 playing an important role in the inhibition of ferroptosis, a large number of studies have shown that natural antioxidants such as vitamin E, thioredoxin, and mitoquinone can also participate in the inhibition of ferroptosis.[74,75,76] Recent research discovered that inducible nitric oxide synthase (iNOS)/NO · abundance modulates susceptibility to ferroptosis in macrophages/microglia.[77] The free radical-capturing antioxidant tetrahydrobiopterin (BH4) inhibits ferroptosis by reducing lipid peroxidation.[78] Furthermore, NRF2 can play an important role in ferroptosis through many different pathways.[79,80,81,82,83,84,85]
Cancer cells will change the normal mechanism of iron metabolism for proliferation, and abnormal iron metabolism is closely related to the occurrence and development of leukemia.[86] Patients with leukemia need a large number of red blood cell transfusions due to disturbance of erythropoiesis and anemia caused by chemotherapy, so iron overload often occurs. Abnormal iron metabolism will seriously affect normal hematopoiesis. The expression of TFR1 in leukemic cells is generally higher than that in normal controls, and its level may be directly related to the differentiation of AML.[87] However, iron depletion caused by TFR1 inhibition can damage the proliferation and differentiation of hematopoietic progenitor cells and reduce the regeneration potential of HSCs.[88] TFR2 is also upregulated in AML subtypes (AML1, AML2, and AML6). Some studies have shown that the expression of TFR2 α subtypes may be positively correlated with a good prognosis.[89,90,91] Excess iron and ROS catalytic products promote the malignant transformation of HSCs through nicotinamide adenine dinucleotide phosphate oxidase (NOX) and subsequent GSH depletion.[92] At the same time, ROS may also promote the transformation process of AML.[93] In monocyte AML, the increase of ROS can induce apoptosis of adjacent natural killer (NK) cells and CD4 and CD8 T cells through poly-ADP-ribose polymerase-1 (PARP1), and invalidate the subsequent anti-leukemia response.[94] Serum ferritin is also frequently increased in patients with leukemia and is associated with poor prognosis in patients undergoing chemotherapy[95,96,97,98] and patients receiving allogeneic stem cell transplantation.[99] In patients with AML, overexpression of ferritin heavy chain (FTH) leads to chemotherapy resistance through nuclear factor-kappa B (NF-κB) pathway and pro-oxidative pathway.[95] It is worth noting that the low expression of ferroportin in AML seems to be associated with improved prognosis and higher chemosensitivity.[100]
In recent years, studies related to ferroptosis have emerged, and many studies have shown that ferroptosis is closely related to the occurrence and development of tumors.[26,38,101,102,103,104] Here, we focus on AL and report that ferroptosis affects the occurrence and development of AL through various pathways, including various signaling pathways, natural extracts, drugs, compounds, ferroptosis-related molecules, and so on [Figure 3 and Table 1].
Ferroptosis-related compounds, natural extracts, and drugs for acute leukemia and their mechanisms.
Ferroptosis-related compounds, natural extracts, and drugs for acute leukemia and their mechanisms.
| Compound/drug/natural extract | Disease | Mechanism |
|---|---|---|
| APR-246 | AML | Deplete intracellular GSH and induce lipid peroxide production |
| DHA | AML | Induce autophagy by regulating the activity of AMPK/mTOR/70 kDa ribosomal protein S6 kinase (p70S6K) signaling pathway, accelerate the degradation of ferritin, increase the labile iron pool, promote the accumulation of cellular ROS |
| ATPR | AML | ROS-autophagy-lysosomal pathway |
| Aldh3a2 | AML | Aldh3a2 knockout changes the redox state of cells, affects lipid metabolism, and combines with GPX4 inhibition to activate ferroptosis |
| Sulfasalazine | AML | Inhibit cystine importer SLC7A11/xCT and lead to depletion of GSH bank and oxidative stress-dependent cell death |
| Typhaneoside | AML | Induce autophagy by promoting the activation of the AMPK signal pathway and then increase the labile iron pool and promote the accumulation of cellular ROS |
| Chlorido[N,N′-disalicylidene-1,2-phenylenediamine] iron(III) complexes | AML | Increase the production of ROS |
| Ungeremine | AML | Activate caspase, change metalloproteinases, increase ROS production |
| Epunctanone | AML | The addition of deferoxamine or ferrostatin-1 decreased its cytotoxicity |
| Natural triterpene saponin ardisiacrispin B | AML | The addition of deferoxamine or ferrostatin-1 decreased its cytotoxicity |
| HD | ALL | Increase the accumulation of ROS and decrease GSH and GPX4 |
| SCHL | ALL | The addition of deferoxamine or ferrostatin-1 decreased its cytotoxicity |
| Aridanin | ALL | The addition of deferoxamine or ferrostatin-1 decreased its cytotoxicity |
| PAA | T-ALL | Increase ROS production, induce autophagy through AMPK/mTOR and LC3 signaling pathways, and cause GSH downregulation |
Aldh3a2: aldehyde dehydrogenase 3a2; ALL: Acute lymphocytic leukemia; AML: Acute myeloid leukemia; AMPK: Adenosine monophosphate-activated protein kinase; ATPR: 4-Amino-2-trifluoromethyl-phenyl retinate; DHA: Dihydroartemisinin; GPX4: Glutathione peroxidase 4; GSH: Glutathione; HD: Hydnocarpin D; LC3: Microtubule-associated protein 1 light chain 3; mTOR: Mechanistic target of rapamycin; PAA: Poricoic acid A; ROS: Reactive oxygen species; SCHL: Soyauxinium chloride; SLC7A11: Solute carrier family 7 member 11; T-ALL: T cell ALL; xCT: System Xc-consists of light chain subunit SLC7A11.
Long non-coding ribonucleic acids (lncRNAs) are transcripts of >200 nucleotides and usually do not encode proteins. They play important physiological roles in the body and can regulate epigenetics, the cell cycle, and cell differentiation. Previous studies have shown that lncRNAs can participate in the process of iron-related death in tumors.[105,106,107,108] Zheng et al[109] identified seven lncRNAs (AP001266.2, AC133961.1, AF064858.3, AC007383.2, AC008906.1, AC026771.1, and KIF26BAS1) associated with ferroptosis. Those lncRNAs are related to GSH metabolism and tumor immunity and have been proven to be able to predict the prognosis of AML, providing insights for the development of new AML treatment strategies. Wang et al[110] found a nuclear lncRNA (LINC00618) with low expression in leukemia but high expression after vincristine (VCR) treatment. LINC00618 can accelerate ferroptosis by increasing the levels of lipid ROS and iron, reducing the expression of solute carrier family 7 member 11 (SLC7A11) and inhibiting the expression of lymphoid-specific helicase (LSH) (LSH inhibits iron-related death by enhancing transcription after recruitment to the promoter region of SLC7A11). In addition, LINC00618 can promote ferroptosis and apoptosis induced by VCR, and LINC00618 can accelerate the occurrence of iron-related death through apoptosis.
Bioinformatics databases play an increasingly important role in cancer research. Chen et al[11] used ferroptosis-related genes to distinguish two subtypes in the the cancer genome atlas (TCGA) cohort. From the differentially expressed gene (DEG) analysis of these two subtypes, they established an AML prediction model containing 13 genes (ATG3, FAM106A, KLHL9, LCMT2, LRRC40, LZTR1, NCR2, PAFAH2, PCMTD2, PLA2G5, SCARB1, TK1, ZNF576), which was verified in an independent AML cohort. At the same time, the model can also provide a reference for identifying the sensitivity of chemotherapy drugs and ferroptosis inducers in high-risk groups and low-risk groups. It has the potential value for clinical transformation. In conclusion, these works have revealed the specific relationship between ferroptosis and AML, which may help clinical treatment in the future.
p53 is a well-known tumor suppressor and plays an important role in regulating ferroptosis.[1,112] Some studies have found that the circular RNAs of lysine-specific demethylase 4C (circKDM4C) is downregulated in AML and inhibits the proliferation, migration, and invasion of AML cells. In addition, the upregulation of p53 expression by circKDM4C via hsa-let-7b-5p can reduce ferroptosis.[113] As a promising drug, eprenetapopt (APR-246) can target the mutant protein p53 in AML and promote its binding to target DNA to restore p53 transcriptional activity.[114,115,116,117,118] Birsen et al[119] have shown that AML cell death induced by APR-246 can be inhibited by iron-chelating agents, lipophilic antioxidants, and lipid peroxidation inhibitors, indicating that APR-246 can induce ferroptosis of AML cells. The combination of APR-246 and ferroptosis inducers has synergistic anti-leukemic activity in vitro, and inactivation of the SLC7A11 gene and APR-246 treatment have synergistic anti-leukemic activity in vivo.[119]
The GPX family of enzymes has peroxidase activity. The abnormal expression of GPXs is related to the occurrence and development of tumors.[120,121] Functional enrichment analysis showed that cells with differential expression of GPXs were mainly enriched in oxidative stress, immune regulation, and inflammation, in addition to GSH metabolism and ferroptosis.[122] GPX1 is an important member of the GPX family and is closely related to the occurrence and development of tumors.[123,124] Studies have shown that GPX1 is highly expressed in AML, and high GPX1 expression is associated with poor prognosis. In AML, GPX1 is involved in signal transduction processes such as GSH metabolism and ferroptosis.[125]
By querying the metabolic pathways related to leukemia stem cells and survival rate in multiple AML data sets, Itzykson et al[126] determined that SLC7A11 is related to the poor prognosis of AML, and SLC7A11 can promote the survival of AML cells by encoding xCT cystine importer. The drug sulfasalazine with xCT inhibitory activity has anti-leukemia activity, which can lead to depletion of the GSH bank and oxidative stress-dependent cell death (partially related to ferroptosis). More importantly, in vivo and in vitro experiments confirmed that the combination of anthracycline daunorubicin and sulfasalazine has the best anti-AML effect, indicating that targeting cystine import can be used for AML treatment, and sulfasalazine combined with chemotherapy is a promising treatment strategy for AML patients in the future.[126]
The human immunodeficiency virus type I enhancer binding protein (HIVEP) family has been proven to be involved in many biological processes, such as cell survival, tumor necrosis factor (TNF) signal transduction, and tumor formation. However, its expression pattern, prognostic relevance, and functional significance in AML remain unclear. Ma’s team found in the database that the increased transcription level of HIVEP3 in AML patients is an independent factor affecting the poor prognosis of AML patients, and is related to AML subtype, age, cytogenetic risk, and disease-related molecules.[127] The HIVEP3 co-expression gene cluster is rich in functional pathways related to AML leukemia. Further cell experiments showed that HIVEP3 messenger RNA (mRNA) and protein levels were abnormally expressed in leukemia cells and primitive cells in bone marrow tissue, and HIVEP3 participated in the iron cell apoptosis signal pathway. The research shows that HIVEP3 can be used as an independent prognostic indicator for AML patients. Targeting HIVEP3 to affect the iron death signal pathway of AML may provide a new scheme for AML treatment.[127]
Erastin is a quinazolinone derivative that was found when attempting to identify small synthetic lethal molecules to be used for cells with RAS oncogene expression. In addition, erastin can induce ferroptosis in tumor cells.[1,30] Yu et al[128] found that erastin-induced ferroptosis in HL-60 cells in a dose-dependent manner and enhanced the sensitivity of AML cells to chemotherapeutic drugs such as cytarabine and doxorubicin in a RAS-independent manner, providing a possible solution for AML drug resistance. Previous reports have shown that the transcription factor high mobility group protein 1 (HMGB1) plays an important role in the pathogenesis and chemotherapy resistance of leukemia.[129,130,131,132,133] Ye et al[134] showed that HMGB1 can regulate erastin-induced ferroptosis in HL-60/NRASQ61L cells through the Rasjun N-terminal kinase (JNK)/p38 signaling pathway, informing the mechanism by which HMGB1 modulates ferroptosis in leukemia.
The resistance of tumor cells to existing anticancer drugs hinders the success of tumor chemotherapy. Many natural products show cytotoxicity against tumor cells. Ungeremine induces ferroptosis by activating caspases, changing the mitochondrial membrane potential (MMP), and increasing ROS production.[135] Typhanthin (typhneoside, TYP) is the main flavonoid in the extract of pollen typhae. In AML, TYP can activate the adenosine monophosphate (AMP)-activated protein kinase (AMPK) signaling pathway, induce autophagy, accelerate the accumulation of ferritin, promote the accumulation of ROS, and eventually lead to ferroptosis.[136] Mbaveng et al[137] showed that epunctanone induces apoptosis and ferroptosis in CCRF-CEM cells by changing the MMP and increasing ROS production.
The naturally occurring oleanane-type triterpene saponin ardisiacrispin B, isolated from the fruit of Ardisia kivuensis Taton (Myrsinaceae), induces apoptosis and ferroptosis of CCRF-CEM cells by activating promoter caspases 8 and 9 and effector caspases 3 and 7, modulating the MMP, and increasing the production of ROS.[138]
In addition to some natural products that can induce ferroptosis in AML, some compounds, molecules, and artificially designed drugs can also be useful. One study has shown that the expression level of adrenomedullin (ADM) is related to the expression of genes involved in leukemogenesis, cell proliferation regulation, and ferroptosis, providing insights for further exploration of new therapeutic strategies for AML.[139] Dihydroartemisinin (DHA) has been reported to inhibit the growth of lymphocytic leukemia.[140] However, the mechanism of its action in AML is not clear. Du et al[141] found that DHA can activate autophagy, promote ferritin-related lysis, and increase intracellular ROS accumulation by affecting the activity of the AMPK/mTOR (mTOR: Mechanistic target of rapamycin)/70 kDa ribosomal protein S6 kinase (p70S6K) signaling pathway, ultimately leading to ferroptotic cell death. 4-Amino-2-trifluoromethyl-phenyl retinate (ATPR) is an all-trans retinoic acid (ATRA) derivative designed by Li et al[142] and has been shown to be more effective than ATRA in many tumors. ATPR has also been found to cause autophagy-induced ferroptosis in vivo and in vitro in studies targeting AL.[142,143,144,145,146,147,148] Leukemic cells prevent oxidative damage by oxidizing long-chain aliphatic aldehydes via aldehyde dehydrogenase 3a2 (Aldh3a2). The study of Yusuf et al[149] shows that knocking down Aldh3a2 can affect the lipid metabolism and redox state of AML cells and induce ferroptosis. Importantly, ferroptosis caused by Aldh3a2 depletion have a synergistic effect with the inhibition of GPX4, which may provide a theoretical basis for the combined application of Aldh3a2 inhibitors and cytotoxic therapy.[149] In recent years, iron-based nanodrugs have become a new type of ferroptosis inducer in leukemia.[150,151,152] Luo et al[153] studied the effects of two kinds of iron nanoparticles, 2,3-dimercaptosuccinic acid (DMSA)-coated Fe3O4 nanoparticles (FeNPs) as a ROS inducer and Prussian blue nanoparticles (PBNPs) as a ROS scavenger, on the transcripts of two kinds of leukemic cells (KG1a AML cells and HL60 acute promyelocytic leukemia cells). According to the results, there were 14 common upregulated genes and 4 common downregulated genes; of these genes, FTL, DNM1, and transferrin receptor (TRFC) play an important role in iron metabolism, indicating that the two drugs may cause cytotoxicity to leukemic cells through ferroptosis. It has been reported that the chloro [N-methylethyl] iron(III) complex produces lipid-based ROS and induces ferroptotic cell death in leukemic and neuroblastoma cell lines, suggesting that it can be used as a novel inducer of ferroptosis in leukemic and neuroblastoma cell lines.[154]
ALL is a common hematological tumor characterized by the malignant proliferation of lymphoid progenitor cells. Many important factors are involved in the regulation of ALL.[155,156] It has been reported that the progestin and adipoq receptor family member 3 (PAQR3), a tumor suppressor, inhibits the proliferation and induces apoptosis of human leukemia cells, but its effect on cell proliferation and iron-related death and related regulatory mechanisms needs to be further studied.[157] Jin et al[158] showed that low expression of PAQR3 in ALL inhibits the proliferation of ALL cells and aggravates ferroptosis. Further experiments showed that PAQR3 binds to NRF2 and regulates its expression in ALL through ubiquitination, thus affecting cell proliferation and ferroptosis. ALL is closely related to ferroptosis. Marcotte’s team performed whole-genome CRISPR/Cas deletion screening on a panel of seven B-ALL cell lines.[159] The results showed that compared with other cancers, the survival of ALL cell lines depended on several unique metabolic pathways, including sensitivity to GPX4 depletion and induction of iron cell apoptosis. Detailed molecular analysis showed that B-ALL cells showed high steady-state oxidative stress potential, low buffer capacity, and GPX4-independent secondary lipid peroxidation detoxification pathway, suggesting that they were sensitive to ferroptosis. Finally, Marcotte used samples from B-ALL patients to verify that B-ALL is indeed sensitive to iron-related apoptosis.[159]
Ferroptosis is characterized by the generation of lipid-based ROS and lipid peroxidation.[160] Several ROS-generating enzymes contain iron or iron derivatives as essential cofactors for their proper function, such as LOX, nicotinamide adenine dinucleotide phosphate hydride (NADPH) oxidase (NOX), xanthine oxidase, and cytochrome P450 enzymes.[6] LOXs are key enzymes that catalyze the oxygenation of polyunsaturated fatty acyl groups to lipid hydroperoxides,[161] while GPX family members are responsible for the reduction of hydrogen and lipid peroxides.[162] It is also reported that the regulatory effect of LOXs on RSL3-induced ferroptosis in ALL cells. Their research indicates that RSL3, an inhibitor of GPX4, triggers lipid peroxidation, ROS generation, and cell death in ALL cells. All of these events were prevented by the presence of iron statin-1 (Fer-1), a small molecular inhibitor of lipid peroxidation. Importantly, LOX inhibitors, including the selective LOX12/15 inhibitor baicalein and the pan-LOX inhibitor nordihydroguaiaretic acid (NDGA), protect cells from RSL3-stimulated lipid peroxidation, ROS production, and cell death, suggesting that LOXs contribute to ferroptosis.[163]
Previously, many natural extracts were shown to be involved in the induction of ferroptosis in AML. In ALL, some compounds and drug components are also associated with ferroptosis. Hydnocarpin D (HD) is a bioactive flavonoid lignin with good antitumor activity.[164,165] HD inhibits the proliferation of the T cell ALL (T-ALL) cell lines Jurkat and Molt-4 in vitro by inducing cell cycle arrest, which results in apoptosis. In addition, HD increases the level of microtubule-associated protein light chain 3 (LC3)-II, a marker of autophagy, and the formation of autophagic lysosomal vacuoles. The inhibitory effect of ATG5/7 gene knockout or 3-MA pretreatment on autophagy partially enhanced the apoptosis induced by HD, suggesting that autophagy enhances the influence of HD. Moreover, this cytotoxic autophagy caused ferroptosis, which was characterized by the accumulation of lipid ROS and a decrease in GSH and GPX4, and conversely, inhibition of autophagy hindered cell ferroptosis.[166] Soyauxinium chloride (SCHL) is a naturally occurring indole-quinazoline-type alkaloid. Some studies found that SCHL induced cytotoxicity of CCRF-CEM leukemia cells through caspase 3, 7, 8, and 9 activation, MMP alteration, and increased ROS generation, while the presence of Fer-1 (ferrostain-1) or DFA (deferoxamine; an iron-related death inhibitor) decreased SCHL cytotoxicity by 7.11- and 4.64-fold, respectively, indicating that SCHL is involved in ferroptosis.[167] Similarly, a naturally occurring N-acetylated oleanolic acid glycoside (aridanin) was cytotoxic to CCRF-CEM leukemia cells, and when nec-1 (necrosis inhibitor), Fer-1 (iron-related death inhibitor), and DFA (iron-related death inhibitor) were added, allicin was 2.74-, 1.61-, and 2.70-fold less cytotoxic, respectively, indicating its ability to induce necrosis and ferroptosis in CCRF-CEM cells.[168] Poricoic acid A (PAA) is the main chemical component of the surface layer of mushroom Poria cocos, which has a protective effect on various diseases. Sun et al[169] found that PAA can trigger apoptosis of T-ALL cells by increasing ROS production, induce autophagy through AMPK/mTOR and LC3 signaling pathways, and cause GSH downregulation and malonaldehyde (MDA) upregulation, leading to ferroptosis. The in vitro experiments also confirmed the inhibitory effect of PAA on T-ALL, indicating that PAA may be a new therapeutic strategy for patients with T-ALL.
ATLL is an invasive disease caused by human T cell leukemia virus type 1 (HTLV-1) infection. The therapeutic effect in patients is limited by chemotherapy resistance. Therefore, there is an urgent need to develop new and effective strategies.[170,171] Artesunate (ART) is a widely used antimalarial compound that has been proven to have cytotoxicity.[172] However, the mechanism of its action in ATLL is not clear. Ishikawa et al[173] showed that ART has a cytotoxic effect on ATLL cells, which can be partially reversed by treatment with ROS scavengers, iron-chelating agents, and inhibitors of necrosis or ferroptosis, indicating that ART can induce ferroptosis in ATLL cells and kill tumor cells.
There are currently fewer studies on ferroptosis in chronic leukemia than in AL. Although it has been proven that typhanthin and Chlorido[N, N'-disalicylidene-1,2-phenylenediamine]iron(III) complexes can induce ferroptotic cell death in the K562 cell line (CML cells), sufficient experimental evidence is lacking. In the future, a large number of studies are needed to explain the role of ferroptosis in chronic lymphocytic leukemia (CLL) and chronic myelocytic leukemia (CML).[136,154]
In this review, we provided the definition, basic characteristics, and history of ferroptosis, briefly described the mechanism of ferroptosis, illustrated the relationship between abnormal iron metabolism and leukemia illustrated the relationship between abnormal iron metabolism and leukemia, and focused on recent progress in the understanding of the role of ferroptosis in leukemia. At present, leukemia is one of the most common malignant tumors and major disorders affecting human health. In recent years, with advances in radiotherapy, chemotherapy, HSC transplantation, and the emergence of new treatments such as targeted therapy, biotherapy, and cell therapy, the prognosis of patients with leukemia has been greatly improved. However, due to various factors, the overall survival time of patients with leukemia is still very short, and new treatment strategies to improve the survival time of patients still need to be developed. Ferroptosis is a form of oxidative cell death characterized by accumulated iron and excessive lipid peroxidation. Previous studies of ferroptosis have shown outstanding antitumor effects. The tumor-inhibitory effect of ferroptosis in fibrosarcoma, prostate cancer, and osteosarcoma has been confirmed. Targeting ferroptosis may become another innovative therapeutic strategy for the treatment of tumors. There has been much research to reveal the mechanism and utility of ferroptosis in hematological malignant tumors. Many natural drug extracts show great cytotoxicity against leukemic cells by inducing ferroptosis. Some lncRNAs and circular RNAs (circRNAs) also show the ability to induce ferroptosis in hematological malignant tumors, and some molecules participate in ferroptosis by regulating key molecules such as TP53, NRF2, GPX4, and GSH, which regulate ferroptotic cell death. Moreover, in addition inducing leukemic cell death, inducing ferroptosis can also assist in treatment by increasing sensitivity to drugs and chemotherapy. However, we have only just begun to understand the role of ferroptosis in leukemia. The results of studies on the role of ferroptosis in leukemia are still deficient. In the future, more in-depth research on the mechanism of ferroptosis in leukemia will contribute to the development of effective anticancer drugs. There is still great potential for the study of ferroptosis in leukemia.
None.
Lyu TX, Li XD, Song YP. Ferroptosis in acute leukemia. Chin Med J 2023;136:886–898. doi: 10.1097/CM9.0000000000002642
